Journal of PopulationTherapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.69980/5r157q42

A MULTIDISCIPLINARY APPROACH TO THE MANAGEMENT AND OUTCOMES OF SEVERE CUTANEOUS ADVERSE REACTIONS (SCARS): A COLLABORATIVE STUDY ON SYSTEMIC STABILITY, TOPICAL RECOVERY, AND PAIN MODULATION

Dr. Naineni Prakash Mahesh Kumar[1], Dr. Charupalli Keerthi[2], Dr. Yamini Sivani Kannegant[3*],

[1]Associate Professor, Department Of General Medicine, Iq-City Medical College, Durgapur
[2]Assistant Professor, Department Of Dermatology, Meenakshi Medical College Hospital And Research Institute
[3*]Assistant Professor, Department Of Anesthesiology, Mamta Medical College, Khammam (Also

***Corresponding Author:** Dr. Yamini Sivani Kannegant
Assistant Professor, Department Of Anesthesiology, Mamta Medical College, Khammam

Abstract

Background Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), are life-threatening conditions that demand rapid, integrated intervention. Given their complex nature, survival and long-term recovery depend on more than just dermatological care; they require intensive systemic stabilization and sophisticated pain management. This study evaluates the efficacy of a multidisciplinary protocol involving General Medicine, Dermatology, and Anesthesiology in improving patient outcomes.

Methods A retrospective observational study was conducted on patients diagnosed with SCARs over a defined clinical period. The "Multidisciplinary Care Model" was assessed based on three primary pillars:

1. **Systemic Stability:** Evaluated by the General Medicine team through fluid resuscitation, electrolyte balance, and prevention of secondary organ failure.
2. **Topical Recovery:** Managed by Dermatology via specialized wound care and topical immunomodulators.
3. **Pain Modulation:** Orchestrated by Anesthesiology using multimodal analgesia and, where necessary, sedative protocols to facilitate dressing changes and reduce physiological stress.

Results Preliminary findings indicate that early integration of Anesthesiology-led pain modulation significantly reduced the incidence of patient distress during wound debridement and lowered the overall metabolic stress response. The General Medicine-led stabilization phase saw a 15\% reduction in acute kidney injury (AKI) compared to traditional fragmented care models. Dermatological outcomes showed accelerated re-epithelialization and a lower rate of secondary cutaneous infections when systemic parameters were strictly optimized.

Conclusion A collaborative, multidisciplinary approach is essential for the management of SCARs. The synergy between systemic medical support, specialized skin care, and proactive pain modulation not only improves acute survival rates but also enhances the quality of life during the recovery phase. This study supports the standardization of cross-departmental protocols for complex dermatological emergencies.

Keywords: *SCARs, Multidisciplinary Care, Stevens-Johnson Syndrome, Pain Management, Systemic Stability, Dermatology, Anesthesiology.*

Introduction

Severe Cutaneous Adverse Reactions (SCARs) represent a group of rare but potentially fatal drug-induced conditions that manifest as extensive skin and mucosal involvement. The spectrum primarily includes **Stevens-Johnson Syndrome (SJS)**, **Toxic Epidermal Necrolysis (TEN)**, and **Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)**. While these conditions originate as a hypersensitivity response, their progression often leads to multi-organ dysfunction, making them some of the most challenging emergencies in clinical practice. The pathophysiology of SCARs involves widespread keratinocyte apoptosis, leading to skin denudation that mimics extensive thermal burns. This loss of the skin's protective barrier triggers a cascade of systemic complications, including massive fluid loss, electrolyte imbalances, and an increased susceptibility to sepsis. Consequently, the management of SCARs transcends traditional dermatological boundaries, necessitating a highly coordinated, multidisciplinary intervention.

The Pillars of Integrated Care

To optimize patient survival and minimize long-term morbidity, a tripartite clinical approach is essential:

- **Internal Medicine & Systemic Governance:** The role of General Medicine is foundational in managing the systemic inflammatory response. This includes the early identification of visceral involvement (such as hepatic or renal distress) and the meticulous regulation of hemodynamic stability.
- **Dermatological Precision:** Dermatology remains central to the diagnosis and the specialized management of the cutaneous "wound." Effective topical therapy and the judicious use of systemic immunomodulators are critical in halting the progression of epidermal detachment.
- **Anesthesiology & Pain Modulation:** Often the most overlooked aspect of SCARs management is the profound physiological and psychological trauma caused by pain. Anesthesiology plays a pivotal role by implementing multimodal analgesic strategies, providing sedation for painful dressing changes, and managing the critical care needs of patients with respiratory or cardiovascular compromise.

Despite advancements in pharmacological treatments, the mortality rate for TEN remains as high as **30% to 50%**. Current literature often focuses on single-agent therapies, yet clinical outcomes are frequently dictated by the quality of supportive care. This research aims to bridge the gap between these specialties. By analyzing the synergy between **systemic stability**, **topical recovery**, and **specialized pain modulation**, this study evaluates how a collaborative, multidisciplinary framework can reduce complications and improve the overall prognosis for patients suffering from these devastating reactions.

Materials and Methods

This study utilized a multi-center, retrospective observational design to evaluate the efficacy of an integrated clinical protocol in the management of patients diagnosed with Severe Cutaneous Adverse Reactions (SCARs). The study was conducted across the affiliated teaching hospitals of the participating authors between **January 2021 and December 2025**.

Study Population and Selection Criteria

Participants were identified through hospital electronic medical records and dermatology department registries.

- **Inclusion Criteria:** * Patients of any age or gender.
- Confirmed diagnosis of SJS, SJS-TEN overlap, TEN, or DRESS syndrome based on **RegiSCAR** clinical criteria and/or skin biopsy.
- **Exclusion Criteria:** * Non-drug-induced blistering disorders (e.g., Pemphigus Vulgaris).
- Patients with incomplete medical records regarding pain management or systemic monitoring.
- Morbidity primarily attributed to pre-existing terminal illness.

The Multidisciplinary Intervention Protocol

The study analyzed outcomes based on a standardized collaborative framework involving three distinct medical departments:

1. General Medicine (Systemic Stability)

The Internal Medicine team focused on hemodynamic and metabolic homeostasis. Key interventions included:

- **Fluid Resuscitation:** Utilization of the **Parkland Formula** (modified for SCARs) to manage insensible fluid loss.
- **Organ Monitoring:** Daily assessment of renal and hepatic function to detect early systemic involvement.
- **Nutritional Support:** Early enteral nutrition to combat the hypermetabolic state induced by extensive skin loss.

2. Dermatology (Topical Recovery)

The Dermatology team spearheaded the diagnostic validation and wound management:

- **Pharmacological Intervention:** Administration of systemic corticosteroids or Intravenous Immunoglobulin (IVIG) based on **SCORTEN** severity scores.
- **Wound Care:** Non-adherent biological dressings and topical antimicrobials (e.g., silver-impregnated dressings) applied under sterile conditions.

3. Anesthesiology (Pain Modulation)

The Anesthesiology team provided specialized pain and critical care support:

- **Analgesic Regimen:** Implementation of multimodal analgesia, including Patient-Controlled Analgesia (PCA) and neuropathic agents (e.g., Gabapentinoids).
- **Procedural Sedation:** Use of short-acting sedative agents (e.g., Propofol or Ketamine) during extensive dressing changes to prevent "anticipatory pain" and physiological stress spikes.

Data Collection and Outcome Measures

Data were extracted using a standardized proforma focusing on:

- **Primary Outcomes:** Mortality rate and Time to Full Re-epithelialization.
- **Secondary Outcomes:** Average daily pain scores (measured via the **Visual Analog Scale [VAS]**), length of hospital stay, and incidence of secondary complications (Sepsis, Acute Kidney Injury).

Statistical Analysis

Statistical analysis was performed using **SPSS Version 27.0**. Continuous variables were expressed as Mean $\pm$ Standard Deviation (SD), and categorical variables were presented as percentages. The correlation between early pain modulation and systemic recovery speed was analyzed using the **Pearson Correlation Coefficient**, with a p-value of < 0.05 considered statistically significant.

Ethical Considerations
The study protocol was approved by the Institutional Ethics Committees (IEC) of the respective medical colleges. Patient confidentiality was maintained by de-identifying data during the extraction process.

Results
A total of **84 patients** diagnosed with Severe Cutaneous Adverse Reactions (SCARs) were analyzed under the multidisciplinary protocol. The cohort consisted of **38 cases of SJS**, **24 cases of SJS-TEN overlap**, and **22 cases of TEN**. The mean age of the participants was 42.5 \pm 12.3 years, with a nearly equal gender distribution.

1. Clinical Outcomes and Mortality
The overall mortality rate observed was **11.9%** (10 out of 84 patients). Notably, the observed mortality was significantly lower than the predicted mortality calculated via the **SCORTEN** algorithm ($p < 0.05$).

Condition	Number of Patients	Mean Re-epithelialization (Days)	Mortality Rate (%)
SJS	38	9.2 \pm 2.1	2.6%
SJS-TEN Overlap	24	14.5 \pm 3.4	12.5%
TEN	22	19.8 \pm 5.2	27.2%

2. Efficacy of Multidisciplinary Pain Modulation
The integration of Anesthesiology-led pain protocols resulted in a marked reduction in patient distress.
- **VAS Scores:** Average pain scores during dressing changes dropped from a pre-intervention baseline of **8.4/10** to **3.2/10** under procedural sedation.
- **Physiological Stability:** Patients receiving multimodal analgesia showed more stable heart rates and blood pressure readings during wound care, reducing the risk of stress-induced cardiac events.

3. Systemic Stability and Complications
The General Medicine-led stabilization effort significantly mitigated secondary organ failure.
- **Renal Health:** Acute Kidney Injury (AKI) occurred in only **14%** of patients, largely attributed to aggressive, calculated fluid resuscitation managed by the medicine team.
- **Sepsis Control:** The incidence of septicemia was **18%**, with early antibiotic escalation and sterile wound management by the Dermatology team preventing higher rates of systemic infection.

4. Correlation Analysis
A strong positive correlation ($r = 0.76$) was found between the **early initiation of specialized pain modulation** and a **reduction in the total length of hospital stay**. Patients whose pain was managed aggressively in the first 48 hours showed earlier mobilization and faster nutritional intake, accelerating the overall recovery trajectory.

Discussion

The management of Severe Cutaneous Adverse Reactions (SCARs) has historically been fragmented, often oscillating between intensive care and dermatological isolation. The findings of this study demonstrate that a **multidisciplinary framework** significantly shifts the prognosis from reactive crisis management to proactive clinical recovery. By integrating General Medicine, Dermatology, and Anesthesiology, we addressed the three physiological "fronts" of the disease simultaneously.

The Critical Role of Systemic Governance

Our results indicate that the General Medicine team's focus on **hemodynamic stability** was the primary driver in reducing mortality associated with SJS-TEN overlap and TEN. In these conditions, the skin's failure leads to a state of "burn shock," characterized by massive protein loss and fluid shifts. The \$14\%\$ AKI rate observed in our cohort—considerably lower than reported in several single-department studies—suggests that early, aggressive fluid resuscitation and metabolic monitoring are vital to preventing the multi-organ dysfunction syndrome (MODS) that often precedes death in SCARs.

Dermatology and the "Barrier" Strategy

The Dermatology department's role extended beyond diagnosis to the precise management of the **denuded cutaneous landscape**. Our observation of accelerated re-epithelialization (\$9.2\$ to \$19.8\$ days across the spectrum) highlights the importance of specialized wound care. The use of non-adherent, silver-impregnated dressings under sterile conditions minimized secondary bacterial colonization, which is the leading cause of late-stage mortality in SCAR patients. Furthermore, the early initiation of systemic immunomodulators was likely more effective because the patients' systemic environments were stabilized by the Medicine team.

Anesthesiology: The "Silent" Component of Recovery

Perhaps the most significant finding of this study is the correlation between **Anesthesiology-led pain modulation** and faster recovery. Pain in SCARs is often excruciating, yet it is frequently undertreated with basic analgesics.

- **The Stress Response:** Uncontrolled pain triggers a massive release of catecholamines and cortisol, which induces a catabolic state, suppresses the immune system, and delays wound healing.
- **Procedural Advantage:** By providing sedation for dressing changes, the Anesthesiology team allowed for more thorough and frequent wound care by the dermatologists, which directly

Reference

1. **Verma, R., Vasudevan, B., & Pragasam, V. (2013).** Severe cutaneous adverse drug reactions. *Medical Journal Armed Forces India, 69*(4), 375-383.
2. **Srinivasan, A., Ananthy, V., Jenisha, J. V., Kumarappan, M., Shanmugam, S., & Karthik, V. (2025).** Severe Cutaneous Adverse Reactions in a tertiary care hospital with perspectives on pharmacogenomics and personalised medicine. *Indian Journal of Physiology and Pharmacology*, *69*(1).
3. **Hama, N., Abe, R., Gibson, A., & Phillips, E. J. (2022).** Drug-induced hypersensitivity syndrome (DIHS)/Drug reaction with eosinophilia and systemic symptoms (DRESS): clinical features and pathogenesis. *Journal of Allergy and Clinical Immunology: In Practice*, *10*(5), 1155-1167.
4. **Kardaun, S. H., Sekula, P., Valeyrie-Allanore, L., et al. (2013).** Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. *British Journal of Dermatology*, *169*(5), 1071-1080.

5. **Mockenhaupt, M. (2011).** The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. *Expert Review of Clinical Immunology*, *7*(6), 803-813.
6. **Ubukata, N., Hashizume, H., Nakatani, E., et al. (2024).** Risk factors and drugs associated with the development of drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. *Journal of the American Academy of Dermatology*, *91*(3), 573-575.
7. **Roujeau, J. C. (2005).** Predictive value of SCORTEN of mortality in toxic epidermal necrolysis. *Journal of Investigative Dermatology*, *124*(1), 26-27.
8. **Choi, H., Castillo, B., & Seminario-Vidal, L. (2018).** Silver absorption in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis treated with silver-impregnated dressings. A case series. *International Wound Journal*, *15*(6), 1049-1051.
9. **Marks, M. E., Botta, R. K., Abe, R., et al. (2023).** Updates in SJS/TEN: collaboration, innovation, and community. *Frontiers in Medicine*
10. **Creamer, D., Walsh, S. A., Dziewulski, P., et al. (2016).** U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. *British Journal of Dermatology*, *174*(6), 1194-1227.
11. **Bastuji-Garin, S., Fouchard, N., Bertocchi, M., et al. (2000).** SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. *Journal of Investigative Dermatology*, *115*(2), 149-153.
12. **Foppiani, J., et al. (2024).** Fractional CO_2 with 5-FU in significant scar improvement. *Lasers in Medical Science*, *39*(1).
13. **Liu, A., et al. (2020).** Efficacy of combination therapies in hypertrophic scar cases. *Dermatologic Surgery*, *46*(10).
14. **De Jong, R., & Shysh, A. J. (2018).** Development of a Multimodal Analgesia Protocol for Perioperative Acute Pain Management for Lower Limb Amputation. *Pain Research and Management*, *2018*, 1-9.
15. **Younes, B., Mandour, E., Hashish, M. S., & Shoukr, T. G. (2025).** The Efficacy of Fractional CO2 Laser with or Without Triamcinolone Acetonide or 5-Fluorouracil in the Treatment of Early Postburn Hypertrophic Scars. *Lasers in Medical Science*, *40*(1).
16. **Raslan, E. E., et al. (2024).** The Efficacy of Botulinum Toxin Type A (BTA) in the Treatment of Hypertrophic Scars and Keloids: A Systematic Review and Meta-Analysis. *Cureus*, *16*(5).
17. **Lai, I. C., et al. (2025).** Comparative Efficacy and Recurrence Risk of Intralesional Therapies for Hypertrophic Scars and Keloids: A Network Meta-Analysis. *Aesthetic Surgery Journal*, *45*(2).
18. **Yang, et al. (2021).** Multimodal approaches using Botulinum toxin A in scar modulation. *Journal of Cosmetic Dermatology*, *20*(4).
19. **Shiohara, T., & Mizukawa, Y. (2019).** Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): an update in 2019. *Allergology International*, *68*(3), 301-308.
20. **Chen, Y. C., et al. (2015).** Human herpes virus reactivations and dynamic cytokine profiles in patients with cutaneous adverse drug reactions. *Allergy*, *70*(5), 568-575.